Atomoxetine for cognitive impairment in Behcet's disease

Phase 3

• Conditions: Condition 1: Behcet's disease. Condition 2: Cognitive impairment.; Behcet's disease; Mild cognitive impairment, so stated; M35.2; G31.84

• Registration Number: IRCT20211206053288N1
• Lead Sponsor: Tehran University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 8 March 2022

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

Individuals diagnosed with Behcet's disease according to ICBD (International Criteria for Behcet's Disease) criteria
Presence of cognitive impairment detected by following tests: Forward digit span, Backward digit span, Trail making A, Trail making B, Verbal fluency

Exclusion Criteria

History of cognitive impairment before affected by Behcet's disease
Substance use
History of adverse reactions to Atomoxetine

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Score of following cognitive tests: Forward digit span, Backward digit span, Trail making A, Trail making B, Verbal fluency. Timepoint: before intervention and 10 weeks after intervention. Method of measurement: cognitive tests: Forward digit span, Backward digit span, Trail making A, Trail making B, Verbal fluency.